Vor Biopharma Inc. Operating Income
Vor Biopharma Inc. (VOR) reported Operating Income of -$47.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- Vor Biopharma Inc. operating income (loss) for the quarter ending 2026-06-30 was -$47.85M.
- Vor Biopharma Inc. operating income (loss) for the quarter ending 2026-03-31 was -$35.16M.
- Vor Biopharma Inc. operating income (loss) for the quarter ending 2025-12-31 was -$35.96M.
- Vor Biopharma Inc. operating income (loss) for the quarter ending 2025-09-30 was -$28.11M.
- Vor Biopharma Inc. operating income (loss) for fiscal 2025 was -$371.64M.
- Vor Biopharma Inc. operating income (loss) for fiscal 2024 was -$121.19M.
- Vor Biopharma Inc. operating income (loss) for fiscal 2023 was -$126.04M.
- Vor Biopharma Inc. operating income (loss) for fiscal 2022 was -$93.42M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$47.85M 10-Q · filed 2026-08-11 | -$83.01M 10-Q · filed 2026-08-11 | -$118.97M derived: sum of 3 quarters · filed 2026-08-11 | -$147.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$35.16M 10-Q · filed 2026-05-13 | -$71.12M derived: sum of 2 quarters · filed 2026-05-13 | -$99.23M derived: sum of 3 quarters · filed 2026-05-13 | -$373.51M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$35.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$64.07M derived: sum of 2 quarters · filed 2026-03-30 | -$338.35M derived: sum of 3 quarters · filed 2026-08-11 | -$371.64M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$28.11M 10-Q · filed 2025-11-13 | -$302.39M derived: sum of 2 quarters · filed 2026-08-11 | -$335.68M 10-Q · filed 2025-11-13 | -$366.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$274.28M 10-Q · filed 2026-08-11 | -$307.57M 10-Q · filed 2026-08-11 | -$338.89M derived: sum of 3 quarters · filed 2026-08-11 | -$367.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$33.29M 10-Q · filed 2026-05-13 | -$64.60M derived: sum of 2 quarters · filed 2026-05-13 | -$93.11M derived: sum of 3 quarters · filed 2026-05-13 | -$122.15M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$31.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$59.82M derived: sum of 2 quarters · filed 2026-03-30 | -$88.86M derived: sum of 3 quarters · filed 2026-03-30 | -$121.19M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$28.51M 10-Q · filed 2025-11-13 | -$57.55M derived: sum of 2 quarters · filed 2025-11-13 | -$89.87M 10-Q · filed 2025-11-13 | -$118.00M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$29.04M 10-Q · filed 2025-08-12 | -$61.36M 10-Q · filed 2025-08-12 | -$89.48M derived: sum of 3 quarters · filed 2025-08-12 | -$124.80M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$32.33M 10-Q · filed 2025-05-14 | -$60.45M derived: sum of 2 quarters · filed 2025-05-14 | -$95.77M derived: sum of 3 quarters · filed 2025-05-14 | -$127.94M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$28.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$63.44M derived: sum of 2 quarters · filed 2025-03-20 | -$95.61M derived: sum of 3 quarters · filed 2025-03-20 | -$126.04M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$35.32M 10-Q · filed 2024-11-07 | -$67.49M derived: sum of 2 quarters · filed 2024-11-07 | -$97.91M 10-Q · filed 2024-11-07 | -$122.64M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$32.17M 10-Q · filed 2024-08-08 | -$62.60M 10-Q · filed 2024-08-08 | -$87.32M derived: sum of 3 quarters · filed 2024-08-08 | -$111.42M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$30.42M 10-Q · filed 2024-05-09 | -$55.15M derived: sum of 2 quarters · filed 2024-05-09 | -$79.25M derived: sum of 3 quarters · filed 2024-05-09 | -$101.04M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$24.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$48.83M derived: sum of 2 quarters · filed 2024-03-20 | -$70.62M derived: sum of 3 quarters · filed 2024-03-20 | -$93.42M 10-K · filed 2024-03-20 |
| 2022-09-30 | -$24.10M 10-Q · filed 2023-11-07 | -$45.89M derived: sum of 2 quarters · filed 2023-11-07 | -$68.69M 10-Q · filed 2023-11-07 | -$87.00M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$21.79M 10-Q · filed 2023-08-10 | -$44.59M 10-Q · filed 2023-08-10 | -$62.90M derived: sum of 3 quarters · filed 2023-08-10 | -$81.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$22.80M 10-Q · filed 2023-05-11 | -$41.11M derived: sum of 2 quarters · filed 2023-05-11 | -$59.71M derived: sum of 3 quarters · filed 2023-05-11 | -$78.09M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$18.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$36.91M derived: sum of 2 quarters · filed 2023-03-23 | -$55.29M derived: sum of 3 quarters · filed 2023-03-23 | -$69.02M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$18.60M 10-Q · filed 2022-11-10 | -$36.98M derived: sum of 2 quarters · filed 2022-11-10 | -$50.71M 10-Q · filed 2022-11-10 | -$66.38M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$18.38M 10-Q · filed 2022-08-11 | -$32.11M 10-Q · filed 2022-08-11 | -$47.77M derived: sum of 3 quarters · filed 2022-08-11 | -$59.56M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$13.73M 10-Q · filed 2022-05-12 | -$29.39M derived: sum of 2 quarters · filed 2022-05-12 | -$41.18M derived: sum of 3 quarters · filed 2022-05-12 | -$49.22M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$15.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$27.45M derived: sum of 2 quarters · filed 2022-03-14 | -$35.49M derived: sum of 3 quarters · filed 2022-03-14 | -$43.37M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$11.79M 10-Q · filed 2021-11-10 | -$19.82M derived: sum of 2 quarters · filed 2021-11-10 | -$27.70M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$8.04M 10-Q · filed 2021-08-09 | -$15.92M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$7.88M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |